Stockscreener 앱 받기
23.47
0.68%
-0.16
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Analysts Are Bullish on Top Healthcare Stocks: Zymeworks (ZYME), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN
New Highs: Can Hippo Holdings Inc lead its sector in growthQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Aug Analyst Calls: What is the earnings history of Zymeworks IncJuly 2025 Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Zymeworks (NYSE:ZYME) Shares Down 5.5%Here's Why - MarketBeat
Hollywood mark, EVP at Zymeworks, sells $138k in shares By Investing.com - Investing.com Nigeria
Zymeworks (NYSE:ZYME) COO Mark Hollywood Sells 6,120 Shares - MarketBeat
Hollywood mark, EVP at Zymeworks, sells $138k in shares - Investing.com
Zymeworks appoints industry veteran Brian Cherry to board By Investing.com - Investing.com Nigeria
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Zymeworks (NYSE:ZYME) EVP Jeffrey Smith Sells 9,310 Shares - MarketBeat
Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 9,560 Shares - MarketBeat
Zymeworks EVP Smith sells shares for $211,090 By Investing.com - Investing.com Canada
Zymeworks CSO Moore sells $216k in shares By Investing.com - Investing.com Canada
Zymeworks EVP Smith sells shares for $211,090 - Investing.com
Zymeworks CSO Moore sells $216k in shares - Investing.com
Insider Selling: Zymeworks (NYSE:ZYME) CEO Sells 30,424 Shares of Stock - MarketBeat
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy - The Globe and Mail
What's Driving Zymeworks Stock Higher? - Nasdaq
Zymeworks Makes Leadership, Board Changes; Begins CFO Search - marketscreener.com
Zymeworks Reshapes Board and Executive Team to Support Next Phase of Growth - TipRanks
Zymeworks appoints industry veteran Brian Cherry to board - Investing.com
Zymeworks Inc. Announces Chief Financial Officer Changes - marketscreener.com
Biotech Zymeworks shakes up its top team as it refocuses strategy - Stock Titan
HERIZON-GEA-01 Trial Highlights Zymeworks’ Path To $440M Milestones And Growth (ZYME) - Seeking Alpha
Zymeworks (ZYME) Reports Positive Phase 3 Trial Results for Ziih - GuruFocus
Zymeworks reports positive phase 3 Ziihera data; cash runway extended beyond 2028 - Seeking Alpha
Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth - TipRanks
Zymeworks Reports Positive Phase 3 Results for Ziihera® in HER2-Positive Gastroesophageal Adenocarcinoma, Announcing Strategic Priorities for 2026 - Quiver Quantitative
Zymeworks Outlines Strategic Priorities and Outlook for 2026 - The Manila Times
Zymeworks outlines strategic priorities and outlook for 2026 - marketscreener.com
Aug Macro: Is Zymeworks Inc. stock vulnerable to regulatory risksQuarterly Portfolio Summary & Reliable Breakout Stock Forecasts - Улправда
Can Zymeworks Inc. stock hit analyst price targetsWeekly Volume Report & Weekly Top Performers Watchlists - Улправда
Zymeworks Inc. (ZYME) Stock Analysis: A 53.85% Potential Upside In The Biotech Arena - DirectorsTalk Interviews
Earnings Beat: How Zymeworks Inc stock reacts to oil pricesJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - moha.gov.vn
How Zymeworks Inc. stock reacts to oil pricesShare Buyback & Weekly Stock Performance Updates - Улправда
Zymeworks (ZYME) Is Down 5.6% After Positive Phase 3 Ziihera Data Unlocks US$440 Million Milestones - simplywall.st
Will Zymeworks Inc. stock benefit from upcoming earnings reportsTrend Following Strategies & Affordable Trading Plans - ulpravda.ru
Oklahoma City NewsThe Oklahoman - FinancialContent
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial - Benzinga
Q3 2025 Zymeworks Inc Earnings Call Transcript - GuruFocus
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Zymeworks’ Ziihera Sets New Survival Benchmark in First-Line HER2-Positive Gastric Cancer Trial - TipRanks
Zymeworks Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera as Potential New Standard of Care in HER2-Positive First-Line Metastatic GEA - Quiver Quantitative
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit - GlobeNewswire
Redlands Daily Facts - FinancialContent
Paul Andrew Moore Sells 20,110 Shares of Zymeworks (NYSE:ZYME) Stock - MarketBeat
Jeffrey Smith Sells 10,538 Shares of Zymeworks (NYSE:ZYME) Stock - MarketBeat
Insider Selling: Zymeworks (NYSE:ZYME) CEO Sells 54,343 Shares of Stock - MarketBeat
Zymeworks (NASDAQ:ZYME) Stock Price Down 6.8%What's Next? - MarketBeat
Zymeworks (NYSE:ZYME) Stock Price Down 6.1%Should You Sell? - MarketBeat
Zymeworks (ZYME): Biotech under pressure as investors wait for the next catalyst - AD HOC NEWS
Zymeworks Inc: Can ZYME’s Quiet Rally Turn Into a Breakout Story? - AD HOC NEWS
Zymeworks shareholders back directors, executive pay and auditor - MSN
Zymeworks shareholders elect directors and approve compensation at annual meeting - Investing.com Australia
4.73%
0.92%
자본화:
|
볼륨(24시간):